StockUS listing USSTOKNASDAQHealthcareProfitless Growth

Stoke Therapeutics Inc(STOK) Stock Analysis | Healthcare

USD --+0.00%
Reward51Moderate
Risk52Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.75Bn
Reward Ratingⓘ51 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ52 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on STOK to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Stoke Therapeutics Inc?

engages in the development of treatments for severe genetic diseases by upregulating protein expression.

AI Brief Pro

The brief on Stoke Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Stoke Therapeutics Inc?

engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.75B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (51)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.376
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
1269,699 shares
$2.5M
0
9-12months
847,570 shares
$1.5M
0